Literature DB >> 7298802

Peripheral responses to thyroid hormone before and after L-thyroxine therapy in patients with subclinical hypothyroidism.

E C Ridgway, D S Cooper, H Walker, D Rodbard, F Maloof.   

Abstract

Twenty patients with serum levels of T4 and T3 within the normal range but with elevated serum concentrations of TSH were evaluated before and after treatment with L-T4. This therapy increased serum T4 (5.5 +/- 1.1 to 8.8 +/- 1.8 microgram/dl) and T3 (116 +/- 20 to 137 +/- 28 ng/dl) levels. Cardiac systolic time intervals (STI) were significantly (P less than 0.01) reduced by this therapy. The preejection period (123 +/- 18 to 114 +/- 14 msec; n = 12), the change in preejection period (+17 +/- 17 to +6 +/- 15 msec; n = 12), the ratio of preejection period to left ventricular ejection time (0.412 +/- 0.068 to 0.357 +/- 0.063 msec; n = 12), and the interval from the Q wave of the electrocardiogram to the pulse wave arrival time at the brachial artery (224 +/- 10 to 200 +/- 13 msec; n = 10) were consistently reduced. Cardiac STI were significantly correlated with serum TSH and T4 levels, but not with serum T3 levels. Normalization of serum TSH levels was associated with changes in QKd measurements even in those patients with minimal elevations in serum TSH. These studies demonstrate that patients having the combination of elevated TSH but T4 and T3 levels in the normal range have alterations in STI which can be changed significantly by L-T4 in doses which normalize TSH secretion. These data suggest that such patients have a mild form of primary hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298802     DOI: 10.1210/jcem-53-6-1238

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Management of the unexpected result: compensated hypothyroidism.

Authors:  R Benediktsson; A D Toft
Journal:  Postgrad Med J       Date:  1998-12       Impact factor: 2.401

2.  Restoration of euthyroidism does not improve cardiovascular risk factors in patients with subclinical hypothyroidism in the short term.

Authors:  Z Beyhan; K Ertürk; G Uçkaya; E Bolu; H Yaman; M Kutlu
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

Review 3.  Periodic health examination, 1990 update: 1. Early detection of hyperthyroidism and hypothyroidism in adults and screening of newborns for congenital hypothyroidism. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1990-05-01       Impact factor: 8.262

4.  Subclinical hypothyroidism revisited. When is not enough really not enough?

Authors:  D R Goldmann
Journal:  J Gen Intern Med       Date:  1996-12       Impact factor: 5.128

5.  Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?

Authors:  R Jaeschke; G Guyatt; H Gerstein; C Patterson; W Molloy; D Cook; S Harper; L Griffith; R Carbotte
Journal:  J Gen Intern Med       Date:  1996-12       Impact factor: 5.128

Review 6.  Thyroid disease in older patients. Diagnosis and treatment.

Authors:  P Finucane; C Anderson
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 7.  Hypothyroidism as a risk factor for cardiovascular disease.

Authors:  Bernadette Biondi; Irwin Klein
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

8.  Serum free thyroid hormones in subclinical hypothyroidism.

Authors:  A Pacchiarotti; E Martino; L Bartalena; F Aghini-Lombardi; L Grasso; L Buratti; M Falcone; A Pinchera
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

9.  Thyroid dysfunction after radiotherapy and chemotherapy of brain tumours.

Authors:  E A Livesey; C G Brook
Journal:  Arch Dis Child       Date:  1989-04       Impact factor: 3.791

10.  Use of a single thyroxine test to evaluate ambulatory medical patients for suspected hypothyroidism.

Authors:  B J Goldstein; A I Mushlin
Journal:  J Gen Intern Med       Date:  1987 Jan-Feb       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.